A Study of Azelaic Acid (AzA) 15% Gel in the Treatment of Seborrheic Dermatitis of the Face

• Status: Completed
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is to determine whether a medication on the market for other indications is effective and safe in treating seborrheic dermatitis of the face.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer; LEO Pharma
• Collaborator: Bayer
• Treatments: Azelaic acid

Criteria

Inclusion Criteria:

• Stable or exacerbating seborrheic dermatitis in the facial area

Exclusion Criteria:

• Psoriasis

• Atopic dermatitis

• Facial acne and rosacea

• Dermatophytic skin infections

• Parkinson's disease

• Known immunosuppression; HIV infection

• Any condition requiring continuous systemic or topical corticosteroid or antimycotic therapy

• Continuous asthma inhalation treatment requiring > 800 mg corticosteroids

• Any severe disease likely to interfere with the conduct or the planned termination of the study